In his new role at Lupin, Dr. Chagnaud will assume full responsibility for the Company’s European businss including the company strategy for Generics & Specialty business in Western and CEE region including Russia & CIS countries. He will also be responsible for developing Lupin’s core strategy for Inhalation in the developed markets.
Commenting on the appointment, Vinita Gupta, Chief Executive Officer, Lupin Limited said, “Over the years, Lupin has recorded consistent growth across advanced markets like the US and Japan. With Mauric’s rich experience we look forward to building our business in Europe, in particular around Complex generics & Specialty. We are delighted to welcome him into the Lupin family.”
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide rane of branded and generic formulations and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti‐Infective and NSAID space and holds global leadership positions in the Anti‐TB and Cephalosporin segment.
Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by revenues. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
For the financial year ended March 2013, Lupin's Consolidated turnover and Profit after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142 million (USD 242 million) respectively. Please visit http://www.lupinworld.com for more information
